Business News • PR NewsWire • Samsung Bioepis' SB4 and SB2 Investigational Biosimilar Candidates Sustain Comparable Safety Profiles in One-Year Phase 3 Clinical Studies

Samsung Bioepis' SB4 and SB2 Investigational Biosimilar Candidates Sustain Comparable Safety Profiles in One-Year Phase 3 Clinical Studies

Samsung Bioepis' SB4 and SB2 Investigational Biosimilar Candidates Sustain Comparable Safety Profiles in One-Year Phase 3 Clinical Studies

- Positive one-year results show SB4 etanercept and SB2 infliximab investigational biosimilar candidates sustained comparable safety profiles observed in previously announced primary results Ÿ- 24-week results for SB5 adalimumab investigational biosimilar candidate demonstrate...

View More : http://www.prnewswire.com/news-releases/samsung-bioepis-sb4-and-sb2-investigational-biosimilar-candidates-300174457.html

Releted News by prnewswire

2015 Global Competitiveness Top 10 Brands from China Announced by IDG

goExW '50% Off' Thanksgiving Campaign Boosts Wholesale Imports Proposition

U.S. Census Bureau Daily Feature for November 8: First Popularly Elected Black Senator

Samsung Bioepis' SB4 and SB2 Investigational Biosimilar Candidates Sustain Comparable Safety Profiles in One-Year Phase 3 Clinical Studies

Approximately 80% of psoriatic arthritis patients treated with Cosentyx® saw no progression of joint damage as shown in Novartis new two-year observational data

Boehringer Ingelheim Highlights Latest Community and Research Initiatives in Advancing Anticoagulation Care at American Heart Association (AHA) Scientific Sessions 2015